Acrivon Therapeutics, Inc.: capital expenditure payments
Capital expenditure payments for Acrivon Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Acrivon Therapeutics, Inc. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 1,669,000 | USD | 2026-03-19 | 10-K · 0001193125-26-115123 |
| 2024-01-01 | 2024-12-31 | 2,768,000 | USD | 2026-03-19 | 10-K · 0001193125-26-115123 |
| 2023-01-01 | 2023-12-31 | 1,288,000 | USD | 2025-03-27 | 10-K · 0000950170-25-046056 |
| 2022-01-01 | 2022-12-31 | 2,166,000 | USD | 2024-03-28 | 10-K · 0000950170-24-037618 |
| 2021-01-01 | 2021-12-31 | 238,000 | USD | 2023-03-28 | 10-K · 0000950170-23-010331 |
Related financial histories
- Acrivon Therapeutics, Inc.: total assets
- Acrivon Therapeutics, Inc.: total liabilities
- Acrivon Therapeutics, Inc.: stockholders equity
- Acrivon Therapeutics, Inc.: cash and cash equivalents
- Acrivon Therapeutics, Inc.: net income or loss
- Acrivon Therapeutics, Inc.: operating cash flow
- Acrivon Therapeutics, Inc.: financing cash flow
- Acrivon Therapeutics, Inc.: investing cash flow
- Acrivon Therapeutics, Inc.: retained earnings or deficit
- Acrivon Therapeutics, Inc.: basic weighted-average shares
- Acrivon Therapeutics, Inc.: diluted weighted-average shares
- Acrivon Therapeutics, Inc.: basic earnings per share
- Acrivon Therapeutics, Inc.: diluted earnings per share
- Acrivon Therapeutics, Inc.: net property, plant and equipment
- Acrivon Therapeutics, Inc.: share-based compensation expense
- Acrivon Therapeutics, Inc.: operating income or loss
- Acrivon Therapeutics, Inc.: current assets
- Acrivon Therapeutics, Inc.: current liabilities
- Acrivon Therapeutics, Inc.: current accounts payable
- Acrivon Therapeutics, Inc.: operating expenses
- Acrivon Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Acrivon Therapeutics, Inc. / CIK 0001781174
- Captured
- 2026-09-21T17:26:59.936Z
- SEC response SHA-256
aafdc29218ddc50f71e674abb5ae0f0381fdc649ff4106d9841a4b4789848aa4
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001781174.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))